ArticleInfection and drug resistance2025
Diagnostic Utility of Nanopore Sequencing for Tuberculous Serous Effusions.
Article in Infection and drug resistance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- Lymphocyte-Predominant Ascites as a Clue to Peritoneal Tuberculosis: Two Case Reports and a Literature Review.Infection and drug resistance · 2026Article
- Nanopore-targeted sequencing for rapid and accurate diagnosis of tuberculous serous effusions: a prospective evaluation across pleural, peritoneal, and pericardial fluids.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Early and precise diagnosis of tuberculous serous effusions is a huge challenge. Nanopore sequencing is a potentially efficient assay. The objective of the current study was to evaluate the diagnostic accuracy of nanopore sequencing for tuberculous serous effusions using clinical specimens directly, and to provide a new pathway for the early and precise diagnosis of tuberculous serous effusions. Methods: This was a retrospective analysis of the effectiveness of nanopore sequencing as a diagnostic method for tuberculous serous effusions using clinical specimens (pleural fluid, pericardial effusion, and ascitic fluid). Using clinical diagnosis as reference standard, the diagnostic accuracy indicators such as sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and area under the curve (AUC) for the tests in question were evaluated. Results: In total, 132 patients were eligible for inclusion. Nanopore sequencing showed sensitivity of 93.3%, specificity of 85.2%, PPV of 96.1%, NPV of 76.7%, and AUC of 0.89 for tuberculous serous effusions. The diagnostic accuracy of nanopore sequencing was significantly superior than that of Xpert MTB/RIF and culture. Similar results were observed in different types of tuberculous serous effusions (pleural tuberculosis, pericardial tuberculosis, and peritoneal tuberculosis). Conclusion: Nanopore sequencing was efficient for the rapid diagnosis of tuberculous serous effusions and had a very positive effect. For paucibacillary tuberculous serous effusions, nanopore sequencing might become an effective method for detecting pathogenic bacteria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.